Ginkgo Bioworks DNA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.6M-40.9% | —— | $5.74M-37.9% | $6.08M-41.0% | $6.08M-48.1% | ||
| $19.47M-49.1% | $33.4M-23.8% | $38.84M-56.4% | $49.6M-11.7% | $38.23M+0.8% | ||
| $3.1M-24.3% | —— | —— | —— | $4.09M— | ||
| $16.38M-52.0% | —— | —— | —— | $34.14M— | ||
| 84.1%-5.2pp | —— | —— | —— | 89.3%— | ||
| $49.92M-29.6% | $50.13M-34.4% | $69.35M-9.9% | $53.37M-60.2% | $70.92M-48.0% | ||
| $37.83M-4.8% | $46.01M-19.7% | $44.95M-14.0% | $43.28M-34.7% | $39.72M-43.5% | ||
| $90.85M-23.8% | —— | —— | —— | $119.2M— | ||
| -$71.37M+11.9% | -$70.75M+31.7% | -$90.02M-63.1% | -$65.54M+70.6% | -$80.97M+54.5% | ||
| -366.5%-155pp | -211.9%+24.4pp | -231.8%-170pp | -132.1%+265pp | -211.8%+257pp | ||
| -$4.77M-112% | —— | $9.26M+689% | $4.96M-16.7% | -$2.25M-119% | ||
| -$76.14M+8.5% | -$81.39M+24.5% | -$80.75M-42.2% | -$60.58M+72.1% | -$83.22M+49.8% | ||
| -$80K-191% | -$643K-97.8% | $1K+100% | -$283K-249% | $88K+184% | ||
| -$58.58M+11.5% | -$57.09M+35.1% | -$75.85M-99.4% | -$49.2M+76.1% | -$66.15M+59.9% | ||
| -300.8%-128pp | -170.9%+29.6pp | -195.3%-153pp | -99.2%+267pp | -173%+262pp | ||
| -$71.37M+11.9% | -$70.75M+31.7% | -$90.02M-63.1% | -$65.54M+70.6% | -$80.97M+54.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ginkgo Bioworks's revenue?
- Ginkgo Bioworks (DNA) generated $141.3M in revenue over the trailing twelve months, down 37.8% year over year.
- Is Ginkgo Bioworks profitable?
- Ginkgo Bioworks is not currently profitable: it reported a net loss of $304.4M over the trailing twelve months, a -215.4% net margin.
- Where does Ginkgo Bioworks's income statement data come from?
- Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
